{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,24]],"date-time":"2026-07-24T11:03:53Z","timestamp":1784891033283,"version":"3.55.0"},"reference-count":47,"publisher":"MDPI AG","issue":"4","license":[{"start":{"date-parts":[[2026,7,24]],"date-time":"2026-07-24T00:00:00Z","timestamp":1784851200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Med. Sci.","Medical Sciences"],"abstract":"<jats:p>Background\/Objectives: Acutely ill patients in hospital are at high risk for thrombosis, even post-discharge. However, the safest and most effective strategy for thromboprophylaxis in such patients is still under debate. Our aim was to compare the subcutaneous use of low-dose prophylactic enoxaparin versus intermediate-dose tinzaparin. Methods: Patients in an internal medicine clinic of a tertiary hospital in Athens, Greece, with increased risk for thrombosis (PADUA score \u2265 4) received either intermediate-dose tinzaparin (8000 anti-Xa units) or 40 mg enoxaparin as thromboprophylaxis. Efficacy and adverse effects were evaluated and compared up to 14 days post-discharge. Results: A total of 251 patients who received tinzaparin were compared with 95 patients under enoxaparin thromboprophylaxis. No statistically significant difference was found in the number of bleeding and\/or clinically evident thrombotic events between the two groups [6 versus 14 bleeding (p = 0.2603) events and 0 versus 1 venous thrombotic event (p = 0.999) in the enoxaparin and tinzaparin groups, respectively]. Moreover, no difference was found in length of stay [enoxaparin: 10 days (95%CI: 9\u201312 days); tinzaparin: 8 days (95%CI: 8\u201310 days, HR = 1.18, 95%CI: 0.91\u20131.54, p = 0.2] or mortality [11 deaths with enoxaparin (11.58%, 95%CI: 6.59\u201319.55%) and 50 deaths with tinzaparin (19.92%, 95%CI: 15.45\u201325.30%, OR: 1.9, 95%CI: 0.94\u20133.83, p = 0.069)]. The use of thromboprophylaxis for two weeks post-discharge did not result in any bleeding or clinically evident thrombotic events in either group. Conclusions: In our cohort, the use of intermediate-dose tinzaparin was similar to the use of low-dose enoxaparin for patients with a high PADUA score in terms of thrombotic and\/or bleeding events.<\/jats:p>","DOI":"10.3390\/medsci14040425","type":"journal-article","created":{"date-parts":[[2026,7,24]],"date-time":"2026-07-24T10:38:41Z","timestamp":1784889521000},"page":"425","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Intermediate-Dose Tinzaparin Versus Low-Dose Enoxaparin as Thromboprophylaxis in Hospitalized Internal Medicine Patients"],"prefix":"10.3390","volume":"14","author":[{"given":"Aimilios","family":"Kaklamanos","sequence":"first","affiliation":[{"name":"Department of Pathophysiology, School of Medicine, National and Kapodistrian University of Athens, 11527 Athens, Greece"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0002-9894-1142","authenticated-orcid":false,"given":"Vasileios","family":"Serepisios","sequence":"additional","affiliation":[{"name":"Department of Pathophysiology, School of Medicine, National and Kapodistrian University of Athens, 11527 Athens, Greece"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0004-3094-3162","authenticated-orcid":false,"given":"Sofia","family":"Chelioti","sequence":"additional","affiliation":[{"name":"Department of Pathophysiology, School of Medicine, National and Kapodistrian University of Athens, 11527 Athens, Greece"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kalliopi","family":"Zervakou","sequence":"additional","affiliation":[{"name":"Department of Pathophysiology, School of Medicine, National and Kapodistrian University of Athens, 11527 Athens, Greece"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"George","family":"Christodoulou","sequence":"additional","affiliation":[{"name":"Department of Pathophysiology, School of Medicine, National and Kapodistrian University of Athens, 11527 Athens, Greece"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0074-3619","authenticated-orcid":false,"given":"Abraham","family":"Pouliakis","sequence":"additional","affiliation":[{"name":"2nd Department of Pathology, University Hospital \u201cAttikon\u201d, National and Kapodistrian University of Athens, 12461 Athens, Greece"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Konstantina","family":"Mikelopoulou","sequence":"additional","affiliation":[{"name":"Department of Pathophysiology, School of Medicine, National and Kapodistrian University of Athens, 11527 Athens, Greece"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0000-7731-126X","authenticated-orcid":false,"given":"Daphnie","family":"Germanou","sequence":"additional","affiliation":[{"name":"Department of Pathophysiology, School of Medicine, National and Kapodistrian University of Athens, 11527 Athens, Greece"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ilias","family":"Tsinokou","sequence":"additional","affiliation":[{"name":"Department of Pathophysiology, School of Medicine, National and Kapodistrian University of Athens, 11527 Athens, Greece"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4422-1262","authenticated-orcid":false,"given":"Dimitrios Dorotheos","family":"Papadakis","sequence":"additional","affiliation":[{"name":"Department of Pathophysiology, School of Medicine, National and Kapodistrian University of Athens, 11527 Athens, Greece"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christos","family":"Tsironis","sequence":"additional","affiliation":[{"name":"Department of Pathophysiology, School of Medicine, National and Kapodistrian University of Athens, 11527 Athens, Greece"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2556-6230","authenticated-orcid":false,"given":"Theodoros","family":"Androutsakos","sequence":"additional","affiliation":[{"name":"Department of Pathophysiology, School of Medicine, National and Kapodistrian University of Athens, 11527 Athens, Greece"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2026,7,24]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"e67","DOI":"10.1161\/CIR.0000000000000558","article-title":"Heart Disease and Stroke Statistics-2018 Update: A Report From the American Heart Association","volume":"137","author":"Benjamin","year":"2018","journal-title":"Circulation"},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1007\/s11239-006-5572-y","article-title":"The epidemiology of venous thromboembolism in the community: Implications for prevention and management","volume":"21","author":"Heit","year":"2006","journal-title":"J. Thromb. Thrombolysis"},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"1245","DOI":"10.1001\/archinte.162.11.1245","article-title":"Relative impact of risk factors for deep vein thrombosis and pulmonary embolism: A population-based study","volume":"162","author":"Heit","year":"2002","journal-title":"Arch. Intern. Med."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"248","DOI":"10.1038\/s41569-022-00787-6","article-title":"Epidemiology and prevention of venous thromboembolism","volume":"20","author":"Lutsey","year":"2023","journal-title":"Nat. Rev. Cardiol."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"460","DOI":"10.1055\/s-0036-1597901","article-title":"Scoring Systems for Estimating Risk of Venous Thromboembolism in Hospitalized Medical Patients","volume":"43","author":"Barbar","year":"2017","journal-title":"Semin. Thromb. Hemost."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"801","DOI":"10.1160\/TH16-08-0631","article-title":"Risk assessment models for venous thromboembolism in acutely ill medical patients. A systematic review","volume":"117","author":"Stuck","year":"2017","journal-title":"Thromb. Haemost."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"2450","DOI":"10.1111\/j.1538-7836.2010.04044.x","article-title":"A risk assessment model for the identification of hospitalized medical patients at risk for venous thromboembolism: The Padua Prediction Score","volume":"8","author":"Barbar","year":"2010","journal-title":"J. Thromb. Haemost."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"513","DOI":"10.1056\/NEJMoa1111096","article-title":"Rivaroxaban for thromboprophylaxis in acutely ill medical patients","volume":"368","author":"Cohen","year":"2013","journal-title":"N. Engl. J. Med."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"e20230067","DOI":"10.1590\/1677-5449.202300672","article-title":"Evidence-based pharmacological prophylaxis recommendations for venous thromboembolism in hospitalized acutely ill medical patients: A systematic review of clinical practice guidelines","volume":"22","author":"Gabriel","year":"2023","journal-title":"J. Vasc. Bras."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"2167","DOI":"10.1056\/NEJMoa1110899","article-title":"Apixaban versus enoxaparin for thromboprophylaxis in medically ill patients","volume":"365","author":"Goldhaber","year":"2011","journal-title":"N. Engl. J. Med."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"38","DOI":"10.3400\/avd.ra.19-00115","article-title":"Recommendations for VTE Prophylaxis in Medically Ill Patients","volume":"13","author":"Skeik","year":"2020","journal-title":"Ann. Vasc. Dis."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"357","DOI":"10.1177\/1076029613481105","article-title":"Venous thromboembolism in elderly high-risk medical patients: Time course of events and influence of risk factors","volume":"19","author":"Hull","year":"2013","journal-title":"Clin. Appl. Thromb. Hemost."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"927","DOI":"10.1182\/bloodadvances.2020003442","article-title":"American Society of Hematology 2021 guidelines for management of venous thromboembolism: Prevention and treatment in patients with cancer","volume":"5","author":"Lyman","year":"2021","journal-title":"Blood Adv."},{"key":"ref_14","doi-asserted-by":"crossref","unstructured":"Alrashed, A., Cahusac, P., Mohzari, Y.A., Bamogaddam, R.F., Alfaifi, M., Mathew, M., Alrumayyan, B.F., Alqahtani, B.F., Alshammari, A., and AlNekhilan, K. (2022). A comparison of three thromboprophylaxis regimens in critically ill COVID-19 patients: An analysis of real-world data. Front. Cardiovasc. Med., 9.","DOI":"10.3389\/fcvm.2022.978420"},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"204","DOI":"10.5507\/bp.2021.031","article-title":"Fixed-dose enoxaparin provides efficient DVT prophylaxis in mixed ICU patients despite low anti-Xa levels: A prospective observational cohort study","volume":"166","author":"Benes","year":"2022","journal-title":"Biomed. Pap. Med. Fac. Univ. Palacky. Olomouc Czech Repub."},{"key":"ref_16","first-page":"101155","article-title":"Adjusted versus fixed doses of LMWHs in trauma patients: A systematic review and meta-analysis","volume":"41","author":"Grange","year":"2022","journal-title":"Anaesth. Crit. Care Pain. Med."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"2254","DOI":"10.1182\/bloodadvances.2020001804","article-title":"Dose-adjusted enoxaparin thromboprophylaxis in hospitalized cancer patients: A randomized, double-blinded multicenter phase 2 trial","volume":"4","author":"Zwicker","year":"2020","journal-title":"Blood Adv."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"1064","DOI":"10.1345\/aph.1L194","article-title":"Low-molecular-weight heparins in renal impairment and obesity: Available evidence and clinical practice recommendations across medical and surgical settings","volume":"43","author":"Nutescu","year":"2009","journal-title":"Ann. Pharmacother."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"817","DOI":"10.1055\/s-0037-1613090","article-title":"Dosing in heavy-weight\/obese patients with the LMWH, tinzaparin: A pharmacodynamic study","volume":"87","author":"Hainer","year":"2002","journal-title":"Thromb. Haemost."},{"key":"ref_20","doi-asserted-by":"crossref","unstructured":"Reardon, B., Pasalic, L., Lippi, G., and Favaloro, E.J. (2026). Heparin Anticoagulant Therapy and Its Monitoring. Biomolecules, 16.","DOI":"10.3390\/biom16030425"},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"248","DOI":"10.1177\/10600280251349582","article-title":"The Rates of Bleeding and Venous Thromboembolism with Reduced-Dose Enoxaparin for Thromboprophylaxis in Low-Weight Surgical Patients: A Retrospective Cohort Study","volume":"60","author":"Hakeam","year":"2025","journal-title":"Ann. Pharmacother."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"867","DOI":"10.1097\/TA.0000000000002024","article-title":"Inability to predict subprophylactic anti-factor Xa levels in trauma patients receiving early low-molecular-weight heparin","volume":"85","author":"Imran","year":"2018","journal-title":"J. Trauma. Acute Care Surg."},{"key":"ref_23","first-page":"94","article-title":"A fixed dose approach to thrombosis chemoprophylaxis may be inadequate in heavier critically ill patients","volume":"23","author":"Yi","year":"2021","journal-title":"Crit. Care Resusc."},{"key":"ref_24","doi-asserted-by":"crossref","unstructured":"Akinosoglou, K., Tsoupra, S., Chandroulis, I., Polyzou, E., Dimakopoulou, V., Moulakakis, K., Perperis, A., Karlafti, E., Ztriva, E., and Patriarcheas, V. (2025). Prophylactic vs. Intermediate Tinzaparin Dosage for the Thromboprophylaxis of Acutely Ill Medical Patients at High Risk of Venous Thromboembolism. Med. Sci., 13.","DOI":"10.3390\/medsci13040291"},{"key":"ref_25","doi-asserted-by":"crossref","unstructured":"Munoz-Rivas, N., Aibar, J., Gabara-Xanco, C., Trueba-Vicente, A., Urbelz-Perez, A., Gomez-Del Olmo, V., Demelo-Rodriguez, P., Rivera-Gallego, A., Bosch-Nicolau, P., and Perez-Pinar, M. (2022). Efficacy and Safety of Tinzaparin in Prophylactic, Intermediate and Therapeutic Doses in Non-Critically Ill Patients Hospitalized with COVID-19: The PROTHROMCOVID Randomized Controlled Trial. J. Clin. Med., 11.","DOI":"10.3390\/jcm11195632"},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"10760296231191123","DOI":"10.1177\/10760296231191123","article-title":"Thromboprophylaxis in Hospitalized Non-Critically Ill Patients With Mild-to-Moderate COVID-19 Infection: A Systematic Review and Meta-Analysis","volume":"29","author":"Hafiz","year":"2023","journal-title":"Clin. Appl. Thromb. Hemost."},{"key":"ref_27","doi-asserted-by":"crossref","unstructured":"McRae, H.L., Militello, L., and Refaai, M.A. (2021). Updates in Anticoagulation Therapy Monitoring. Biomedicines, 9.","DOI":"10.3390\/biomedicines9030262"},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"3033","DOI":"10.1016\/j.jtha.2025.06.025","article-title":"A systematic review on anti-Xa monitoring in the therapeutic use of low-molecular-weight heparins","volume":"23","author":"Jaspers","year":"2025","journal-title":"J. Thromb. Haemost."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"2119","DOI":"10.1111\/jth.13140","article-title":"Definition of clinically relevant non-major bleeding in studies of anticoagulants in atrial fibrillation and venous thromboembolic disease in non-surgical patients: Communication from the SSC of the ISTH","volume":"13","author":"Kaatz","year":"2015","journal-title":"J. Thromb. Haemost."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"692","DOI":"10.1111\/j.1538-7836.2005.01204.x","article-title":"Definition of major bleeding in clinical investigations of antihemostatic medicinal products in non-surgical patients","volume":"3","author":"Schulman","year":"2005","journal-title":"J. Thromb. Haemost."},{"key":"ref_31","doi-asserted-by":"crossref","unstructured":"Cauchie, P., and Piagnerelli, M. (2021). What Do We Know about Thromboprophylaxis and Its Monitoring in Critically Ill Patients?. Biomedicines, 22.","DOI":"10.3390\/biomedicines9080864"},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"793","DOI":"10.1056\/NEJM199909093411103","article-title":"A comparison of enoxaparin with placebo for the prevention of venous thromboembolism in acutely ill medical patients. Prophylaxis in Medical Patients with Enoxaparin Study Group","volume":"341","author":"Samama","year":"1999","journal-title":"N. Engl. J. Med."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"614","DOI":"10.1067\/mhj.2003.189","article-title":"Randomized comparison of enoxaparin with unfractionated heparin for the prevention of venous thromboembolism in medical patients with heart failure or severe respiratory disease","volume":"145","author":"Kleber","year":"2003","journal-title":"Am. Heart J."},{"key":"ref_34","unstructured":"PROTECT Investigators for the Canadian Critical Care Trials Group and the Australian and New Zealand Intensive Care Society Clinical Trials Group, Cook, D., Meade, M., Guyatt, G., Walter, S., Heels-Ansdell, D., Warkentin, T.E., Zytaruk, N., Crowther, M., and Geerts, W. (2011). Dalteparin versus unfractionated heparin in critically ill patients. N. Engl. J. Med., 364, 1305\u20131314."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"874","DOI":"10.1161\/01.CIR.0000138928.83266.24","article-title":"Randomized, placebo-controlled trial of dalteparin for the prevention of venous thromboembolism in acutely ill medical patients","volume":"110","author":"Leizorovicz","year":"2004","journal-title":"Circulation"},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"1555","DOI":"10.1007\/s00228-022-03365-4","article-title":"Tinzaparin-a review of its molecular profile, pharmacology, special properties, and clinical uses","volume":"78","author":"Amerali","year":"2022","journal-title":"Eur. J. Clin. Pharmacol."},{"key":"ref_37","doi-asserted-by":"crossref","unstructured":"Akinosoglou, K., Savopoulos, C., Pouliakis, A., Triantafyllidis, C., Markatis, E., Golemi, F., Liontos, A., Vadala, C., Papanikolaou, I.C., and Dimakopoulou, V. (2022). Intensive-Dose Tinzaparin in Hospitalized COVID-19 Patients: The INTERACT Study. Viruses, 14.","DOI":"10.3390\/v14040767"},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"1076029620979592","DOI":"10.1177\/1076029620979592","article-title":"Tinzaparin Safety in Patients With Cancer and Renal Impairment: A Systematic Review","volume":"27","author":"Vathiotis","year":"2021","journal-title":"Clin. Appl. Thromb. Hemost."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"e2611449","DOI":"10.1001\/jamanetworkopen.2026.11449","article-title":"Pharmacologic Thromboprophylaxis in Medical Inpatients: A Systematic Review and Network Meta-Analysis","volume":"9","author":"Marti","year":"2026","journal-title":"JAMA Netw. Open"},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"2463","DOI":"10.1056\/NEJMoa1111288","article-title":"Low-molecular-weight heparin and mortality in acutely ill medical patients","volume":"365","author":"Kakkar","year":"2011","journal-title":"N. Engl. J. Med."},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"1177","DOI":"10.1007\/s10557-025-07806-x","article-title":"Individualizing Thromboprophylaxis: From Fixed Doses to Targeted Low-Molecular-Weight Heparin Use","volume":"40","author":"Kotsiou","year":"2026","journal-title":"Cardiovasc. Drugs Ther."},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"8","DOI":"10.7326\/0003-4819-153-1-201007060-00004","article-title":"Extended-duration venous thromboembolism prophylaxis in acutely ill medical patients with recently reduced mobility: A randomized trial","volume":"153","author":"Hull","year":"2010","journal-title":"Ann. Intern. Med."},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"EVIDoa2200332","DOI":"10.1056\/EVIDoa2200332","article-title":"Enoxaparin versus Placebo to Prevent Symptomatic Venous Thromboembolism in Hospitalized Older Adult Medical Patients","volume":"2","author":"Mottier","year":"2023","journal-title":"NEJM Evid."},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1016\/j.thromres.2019.01.007","article-title":"Monitoring of heparins in antithrombin-deficient patients","volume":"175","author":"Croles","year":"2019","journal-title":"Thromb. Res."},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"1074","DOI":"10.1016\/j.amjmed.2020.01.037","article-title":"Contemporary Meta-Analysis of Extended Direct-Acting Oral Anticoagulant Thromboprophylaxis to Prevent Venous Thromboembolism","volume":"133","author":"Bhalla","year":"2020","journal-title":"Am. J. Med."},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"10760296231181916","DOI":"10.1177\/10760296231181916","article-title":"Analysis of Readmissions Due to VTE-Using Hospital Data to Improve VTE Prophylaxis Compliance: A Quality Improvement Project","volume":"29","author":"Hussain","year":"2023","journal-title":"Clin. Appl. Thromb. Hemost."},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"e12560","DOI":"10.1002\/rth2.12560","article-title":"Post-discharge thrombosis and bleeding in medical patients: A novel risk score derived from ubiquitous biomarkers","volume":"5","author":"Woller","year":"2021","journal-title":"Res. Pract. Thromb. Haemost."}],"container-title":["Medical Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2076-3271\/14\/4\/425\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,24]],"date-time":"2026-07-24T10:58:40Z","timestamp":1784890720000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2076-3271\/14\/4\/425"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,24]]},"references-count":47,"journal-issue":{"issue":"4","published-online":{"date-parts":[[2026,8]]}},"alternative-id":["medsci14040425"],"URL":"https:\/\/doi.org\/10.3390\/medsci14040425","relation":{},"ISSN":["2076-3271"],"issn-type":[{"value":"2076-3271","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7,24]]}}}